Total Payments
$17,962
2024 Payments
$687.49
Companies
24
Transactions
104
Medicare Patients
4,465
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$10,243 (57.0%)
Consulting$4,313 (24.0%)
Food & Beverage$3,292 (18.3%)
Education$75.90 (0.4%)
Gifts$38.80 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $10,225 | 8 | 56.9% |
| Consulting Fee | $4,313 | 2 | 24.0% |
| Food and Beverage | $3,292 | 89 | 18.3% |
| Education | $75.90 | 2 | 0.4% |
| Gift | $38.80 | 2 | 0.2% |
| Entertainment | $17.20 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alimera Sciences, Inc. | $7,606 | 16 | $0 (2023) |
| Allergan, Inc. | $4,568 | 11 | $0 (2022) |
| Optos, Inc. | $3,017 | 3 | $0 (2020) |
| Genentech USA, Inc. | $449.70 | 9 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $439.98 | 12 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $294.07 | 5 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $281.60 | 11 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $231.55 | 4 | $0 (2022) |
| Dutch Ophthalmic, USA | $195.64 | 2 | $0 (2023) |
| Astellas Pharma US Inc | $192.35 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $687.49 | 20 | Genentech USA, Inc. ($266.17) |
| 2023 | $239.49 | 8 | Dutch Ophthalmic, USA ($104.85) |
| 2022 | $1,036 | 22 | Apellis Pharmaceuticals, Inc. ($235.86) |
| 2021 | $3,739 | 16 | Allergan, Inc. ($2,063) |
| 2020 | $3,864 | 7 | Allergan, Inc. ($2,250) |
| 2019 | $8,086 | 17 | Alimera Sciences, Inc. ($6,251) |
| 2018 | $250.76 | 10 | Allergan Inc. ($152.06) |
| 2017 | $59.75 | 4 | NotalVision ($35.79) |
All Payment Transactions
104 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $35.10 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Ophthalmology | ||||||
| 11/06/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/29/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $6.67 | General |
| Category: Ophthalmology | ||||||
| 10/01/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $30.71 | General |
| Category: Ophthalmology | ||||||
| 09/17/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $27.06 | General |
| Category: Ophthalmology | ||||||
| 08/13/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $9.03 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Ophthalmology | ||||||
| 07/15/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $9.35 | General |
| Category: Ophthalmology | ||||||
| 06/13/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $10.70 | General |
| Category: Ophthalmology | ||||||
| 06/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: Ophthalmology | ||||||
| 06/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $32.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/15/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Immunology and Ophthalmology | ||||||
| 05/08/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $47.61 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/23/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $29.71 | General |
| Category: Ophthalmology | ||||||
| 03/09/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $97.79 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/08/2024 | Genentech, Inc. | Susvimo (Drug), Vabysmo | Food and Beverage | In-kind items and services | $102.49 | General |
| Category: Immunology and Ophthalmology | ||||||
| 01/26/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Ophthalmology | ||||||
| 01/17/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $4.91 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/13/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $11.60 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/14/2023 | Harrow Eye, LLC | IHEEZO (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: OPTOMETRY | ||||||
| 11/02/2023 | Dutch Ophthalmic, USA | EVA, combined machine (Device), TISSUEBLUE | Food and Beverage | In-kind items and services | $104.85 | General |
| Category: Ophthalmology | ||||||
| 10/06/2023 | Harrow Eye, LLC | IHEEZO (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: OPTOMETRY | ||||||
| 09/18/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $31.65 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,352 | 17,599 | $1.9M | $728,058 |
| 2022 | 13 | 1,235 | 4,903 | $1.4M | $537,051 |
| 2021 | 12 | 1,083 | 2,359 | $998,456 | $389,038 |
| 2020 | 8 | 795 | 1,765 | $701,559 | $264,880 |
Total Patients
4,465
Total Services
26,626
Medicare Billing
$1.9M
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 40 | 14,700 | $1.1M | $421,328 | 39.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 25 | 238 | $438,494 | $160,621 | 36.6% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 301 | 508 | $146,159 | $50,502 | 34.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 71 | 386 | $125,707 | $41,076 | 32.7% |
| 92134 | Imaging of retina | Office | 2023 | 385 | 913 | $84,709 | $29,377 | 34.7% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 102 | 102 | $34,755 | $10,849 | 31.2% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 384 | 670 | $23,530 | $7,625 | 32.4% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 19 | 53 | $8,548 | $3,749 | 43.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,359 | $1,759 | 32.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 18 | $3,581 | $1,171 | 32.7% |
| J3490 | Unclassified drugs | Office | 2022 | 18 | 112 | $477,420 | $175,591 | 36.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 30 | 236 | $442,274 | $169,019 | 38.2% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 17 | 2,280 | $162,061 | $66,248 | 40.9% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 262 | 418 | $120,258 | $41,907 | 34.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 60 | 289 | $65,386 | $29,922 | 45.8% |
| 92134 | Imaging of retina | Office | 2022 | 341 | 783 | $72,649 | $25,527 | 35.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 66 | 66 | $24,392 | $8,186 | 33.6% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 339 | 576 | $20,229 | $6,663 | 32.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $10,718 | $4,147 | 38.7% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 22 | 54 | $8,710 | $3,967 | 45.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 25 | $4,965 | $1,984 | 40.0% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 20 | 20 | $6,815 | $1,948 | 28.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 22 | $6,319 | $1,942 | 30.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 33 | 388 | $703,102 | $275,121 | 39.1% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 197 | 326 | $93,699 | $34,214 | 36.5% |
About Dr. Nadeem Vaidya, M.D
Dr. Nadeem Vaidya, M.D is a Retina Specialist healthcare provider based in Irvine, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1578616520.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nadeem Vaidya, M.D has received a total of $17,962 in payments from pharmaceutical and medical device companies, with $687.49 received in 2024. These payments were reported across 104 transactions from 24 companies. The most common payment nature is "Honoraria" ($10,225).
As a Medicare-enrolled provider, Vaidya has provided services to 4,465 Medicare beneficiaries, totaling 26,626 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Irvine, CA
- Active Since 01/20/2007
- Last Updated 08/06/2022
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1578616520
Products in Payments
- Iluvien (Drug) $6,275
- OZURDEX (Drug) $4,554
- P200DTx (Device) $3,017
- ILUVIEN (Drug) $1,289
- EYLEA (Biological) $483.08
- Vabysmo (Drug) $266.17
- DEXYCU (Drug) $164.71
- SUSVIMO (Drug) $158.67
- XIPERE (Drug) $151.59
- Izervay (Drug) $144.70
- XIIDRA (Drug) $133.38
- YUTIQ (Drug) $116.89
- EVA, combined machine (Device) $104.85
- Susvimo (Drug) $102.49
- EVA Ophthalmic Surgical System (Device) $90.79
- BEOVU (Drug) $79.42
- EYLEA HD (Biological) $61.36
- Syfovre (Drug) $58.21
- ACTHAR (Biological) $40.98
- None Specified (Medical Supply) $38.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.